Ultragenyx Pharmaceutical Inc. · Brief

Next report

3 days

Nov 3 · after closeest.Q3 FY26

Expected move

±8.8%implied · straddle

14.6817.52

spot 16.10exp Nov 6ATM strike 16ATM straddle 1.67IV 94%

Oct 30 close

Expected move

—≥ implied

Q2 FY26±16.4%▼−3.41%×0.21

quarterimplied−20%0+20%realized×

Q2 FY26±16.4%▼−3.41%×0.21

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 3 report · est.

Bull2 of 3

25disclosed supplier and customer ties in SEC filingsSEC filings

+39.98%change in shares held by the ten largest reporting managers over latest quarter13F · Jun 30 '26

Bear2 of 4

45.00%of revenue from the largest disclosed customer, Kyowa Kirin Co., Ltd.SEC filings

5tracked funds holding RAREN-PORT · Aug 31 '26

AI captions · Sep 16 '26once per report · top 2 per case

RARE report session

No linked exposure.

Oct 20impliedImplied move: ±16.0% into Nov 3 earnings (Oct 20 close).Source

Oct 148-KMaterial agreement: 8-K Item 1.01.Source

Oct 78-KMaterial agreement: 8-K Item 1.01.Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.